Cullinan Therapeutics Reports Positive Initial Phase 1 Data for CLN-978 in Autoimmune Diseases

summarizeSummary

Cullinan Therapeutics reported positive initial Phase 1 clinical data for its T cell engager CLN-978 in patients with rheumatoid arthritis and systemic lupus erythematosus, showing clinical benefit and a favorable safety profile.

check_boxKey Events

• Positive Phase 1 Data for CLN-978

  Initial clinical data from the Phase 1 OUTRACE trials for CLN-978 in treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) showed clinical benefit.

• Clinical Benefit and Remissions

  In SLE patients, 71% showed a significant reduction in hSLEDAI, with 5 achieving DORIS remission. In RA patients, 71% showed improved disease activity, including one DAS28-ESR remission.

• Deep B Cell Depletion

  CLN-978 achieved deep, dose-dependent B cell depletion in peripheral blood and tissue in both SLE and RA patients, indicating a strong mechanism of action.

• Favorable Safety Profile

  The drug was well tolerated across therapeutic dose cohorts (10-30 µg), with most cytokine release syndrome (CRS) events being Grade 1. No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.

auto_awesomeAnalysis

Cullinan Therapeutics announced encouraging initial Phase 1 clinical data for CLN-978 in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The data showed clinical benefit, including remissions, and deep, dose-dependent B cell depletion in both peripheral blood and tissue. The drug demonstrated a favorable safety profile at therapeutic doses, which is critical for advancing a T cell engager in autoimmune indications. This positive early-stage data de-risks a key pipeline asset and could support future financing efforts, especially given the company's previously reported limited cash runway.